Overanticoagulation is associated with renal function decline

Journal of Nephrology

Volumn 26, Issue 4, 2013, Pages 1-8

  van Blijderveen, Jan Cornelis ^a   Verhamme, Katia M ^a   Zietse, Robert ^a   Visser, Loes E ^a   Romio, Silvana A ^a   Buhre, Peter N ^b   Sturkenboom, Miriam C ^a   Hofman, Albert ^a   Straus, Sabine M ^a,c   Stricker, Bruno H ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b STAR Medical Diagnostic Center   (Netherlands)

^c MEDICINES EVALUATION BOARD   (Netherlands)

^d Drug Safety Unit   (Netherlands)

Author keywords

Acenocoumarol; Anticoagulants; Excess anticoagulation; Phenprocoumon; Progression of renal function decline; Warfarin nephropathy

Indexed keywords

ANTIVITAMIN K; CREATININE; PROTHROMBIN;

ACUTE KIDNEY FAILURE; ADULT; AGE; ANTICOAGULATION; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DRUG INDICATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LINEAR REGRESSION ANALYSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; PROTHROMBIN TIME; SEX DIFFERENCE; TREATMENT DURATION;

EID: 84880091674     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000280     Document Type: Article

References (36)

1. Lutter R. United States Food and Drug Administration. Critical Path Initiative: warfarin dosing. 2012. Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm077473.htm. Accessed July 17, 2012.
2. Statistics Netherlands. Population, households and population development. Available at: http://statline.cbs.nl/StatWeb/publication/?VW=T&DM=SLNL&PA=37556&D1=0-44&D2=1,11,21,31,41,51,61,71,81,91,101,l&HD=120119-1058&HDR=G1&STB=T. Accessed January 19, 2012.
3. Dutch Federation of Anticoagulation Clinics (Federatie van Nederlandse Trombosediensten): Summary to the Medical Annual Report 2010 (Samenvatting medische jaarverslagen 2010) Available from: http://www.fnt.nl/media/docs/jaarverslagen/Jaarverslag_FNT_Medisch_2010.pdf Accessed July 17, 2012.
4. Abt AB, Carroll LE, Mohler JH. Thin basement membrane disease and acute renal failure secondary to gross hematuria and tubular necrosis. Am J Kidney Dis. 2000;35(3):533-536.
5. Kabir A, Nadasdy T, Nadasdy G, Hebert LA. An unusual cause of gross hematuria and transient ARF in an SLE patient with warfarin coagulopathy. Am J Kidney Dis. 2004;43(4): 757-760.
6. Brodsky SV, Satoskar A, Chen J, et al. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis. 2009;54(6):1121-1126.
7. Rizk DV, Warnock DG. Warfarin-related nephropathy: another newly recognized complication of an old drug. Kidney Int. 2011;80(2):131-133.
8. Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int. 2011;80(2):181-189.
9. Brodsky SV, Collins M, Park E, et al. Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract. 2010; 115(2):c142-c146.
10. Woo KT, Lee GS, Foo MW, Chan CM. Warfarin-related nephropathy in patients with chronic kidney disease. Kidney Int. 2012;82(1):113, author reply 113-114.
11. Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med. 2009; 150(5):293-300.
12. Crowther MA, Julian J, McCarty D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomized controlled trial. Lancet. 2000;356(9241):1551-1553.
13. Banet GA, Waterman AD, Milligan PE, Gatchel SK, Gage BF. Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio. Chest. 2003;123(2): 499-503.
14. Ageno W, Crowther M, Steidl L, et al. Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial. Thromb Haemost. 2002;88(1):48-51.
15. Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: a randomized, controlled trial. Ann Intern Med. 2002;137(4):251-254.
16. Fondevila CG, Grosso SH, Santarelli MT, Pinto MD. Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation: a prospective, randomized, open study. Blood Coagul Fibrinolysis. 2001;12(1):9-16.
17. Hung A, Singh S, Tait RC. A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization. Br J Haematol. 2000;109(3): 537-539.
18. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003;163(20):2469-2473.
19. Nee R, Doppenschmidt D, Donovan DJ, Andrews TC, et al. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol. 1999;83(2): 286-288+A6-A7.
20. Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy. 2000;20(10): 1159-1166.
21. Pengo V, Banzato A, Garelli E, Zasso A, Biasiolo A. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. Blood Coagul Fibrinolysis. 1993;4(5):739-741.
22. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333(1):11-17.
23. Hofman A, van Duijn CM, Franco OH, et al. The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol. 2011;26(8):657-686.
24. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
25. Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: The Rotterdam Study. Eur Heart J. 2004;25(18):1614-1619.
26. Remme WJ, Swedberg K. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22(17):1527-1560.
27. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population: The Rotterdam Study. Eur Heart J. 1999;20(6):447-455.
28. Teichert M, van Schaik RH, Hofman A, et al. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther. 2009;85(4): 379-386.
29. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2)(Suppl 1):S1-S266.
30. Nieuwhof CM, de Heer F, de Leeuw P, van Breda Vriesman PJ. Thin GBM nephropathy: premature glomerular obsolescence is associated with hypertension and late onset renal failure. Kidney Int. 1997;51(5):1596-1601.
31. Dische S. Radiotherapy of cervical cancer. Clin Obstet Gynaecol. 1985;12(1):203-227.
32. Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int. 2006;69(11):1934-1938.
33. Martins L, Rocha G, Rodrigues A, et al. Lupus nephritis: a retrospective review of 78 cases from a single center. Clin Nephrol. 2002;57(2):114-119.
34. Ozcan A, Ware K, Calomeni E, et al. 5/6 nephrectomy as a validated rat model mimicking human warfarin-related nephropathy. Am J Nephrol. 2012;35(4):356-364.
35. Ware K, Brodsky P, Satoskar AA, et al. Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation. J Am Soc Nephrol. 2011;22(10):1856-1862.
36. Connolly S, Pogue J, Hart R, et al. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903-1912.